CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer Academic Article uri icon

Overview

MeSH Major

  • Colorectal Neoplasms
  • Glutathione
  • Liver Neoplasms
  • Neoplasm Proteins
  • Pyruvate Kinase

abstract

  • Nivolumab and nivolumab plus ipilimumab demonstrated clinically meaningful antitumor activity, durable responses, encouraging long-term OS, and a manageable safety profile in patients with chemotherapy-refractory esophagogastric cancer. Phase III studies evaluating nivolumab or nivolumab plus ipilimumab in earlier lines of therapy for esophagogastric cancers are underway.

publication date

  • October 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2017.76.6212

PubMed ID

  • 30110194

Additional Document Info

start page

  • 2836

end page

  • 2844

volume

  • 36

number

  • 28